The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00282659|
Recruitment Status : Completed
First Posted : January 27, 2006
Last Update Posted : May 21, 2019
|Condition or disease||Intervention/treatment||Phase|
|Coronary Artery Disease Hypertension Dyslipidemia Diabetes||Drug: magnesium L-lactate||Phase 4|
Magnesium is the second most abundant intracellular cation and plays a vital role in many physiologic processes. It has been determined that patients with cardiovascular disease have intracellular magnesium (Mgi) deficiencies. Among the ICD registries in Europe and the United States 64% and 77% of patients also carry the diagnosis of CAD, respectively. Patients with CAD have risk factors that lead to the development and or propagation of atherosclerosis. Paramount among these risk factors are hypertension, dyslipidemia, and diabetes.
Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the effect they have on cholesterol, blood pressure, and blood glucose.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||240 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||The Use of Magnesium to Improve Hemodynamics, Cholesterol, and Glucose Control: A Substudy of AdMag|
|Study Start Date :||January 2006|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||June 2008|
- Blood pressure, cardiac output, systemic vascular resistance, thoracic fluid content, total cholesterol, low density lipoprotein, high density lipoprotein, triglycerides, and blood glucose [ Time Frame: at baseline, 3, and 6 months of follow-up ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00282659
|United States, Connecticut|
|Hartford, Connecticut, United States, 06102-5037|
|Principal Investigator:||Charles M White, PharmD||University of Connecticut School of Pharmacy, Hartford Hospital Division of Drug Information|